> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Curis Lymphoma Study on Partial Hold
- URL: https://www.fdaweb.com/curis-lymphoma-study-on-partial-hold/
- Published: 2022-04-11T12:00:00.000Z
- Updated: 2026-09-14T17:40:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151560

FDA has placed a partial clinical hold on Curis’ TakeAim Lymphoma study, a Phase 1/2 open-label dose escalating clinical trial investigating emavusertib in patients with B-cell malignancies. The company says CDER’s Division of Hematologic Malignancies 2 followed suit by extending a partial hold originally placed by the Division of Hematologic Malignancies 1 on the company’s TakeAim Leukemia study 4/4.

FDA is requesting additional safety, efficacy, and other data relating to emavusertib, including data on rhabdomyolysis and the company's determination of the recommended Phase 2 Dose for emavusertib, according to Curis. The partial holds do not allow any new patients to enroll, and current study participants benefiting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower after agreeing to a revised patient consent form.